Vendor, Herndon, VA
Perfusion Medical, Inc.
UEI XEDJGXP1K889, CAGE 8MYE9
5 awards and $5,208,982 obligated between February 8, 2024 and April 3, 2026, 100% under full and open competition, against 133.6 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Department of the Air Force | $3,709,209 |
| Defense Health Agency | $1,499,773 |
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $5,208,982 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 5 |
| Small Business Set Aside - Total | 5 |
| Purchase Order | 3 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| FA864924P0531Purchase Order, June 21, 2024, Full and Open Competition After Exclusion of Sources, 84 offers | FA8649 USAF SBIR STTR Cntrctng AFRLDepartment of the Air Force | Human Clinical Trial for Safety of PM-208 Anti-Shock DrugNAICS 541715, PSC AC32 | $1,799,970 |
| FA864924P0552Purchase Order, February 8, 2024, Full and Open Competition After Exclusion of Sources, 84 offers | FA8649 USAF SBIR STTR Cntrctng AFRLDepartment of the Air Force | Research and Development of Optimal Dosing and Formulation of PM-208 (Peg-20k/8k) for Af Field UseNAICS 541715, PSC AC32 | $1,799,322 |
| HT942726CE025Definitive Contract, April 3, 2026, Full and Open Competition After Exclusion of Sources, 1 offers | Defense Health AgencyDefense Health Agency | Ind-Enabling Studies of PM-208: a Novel Pre-Hospital Anti-Shock TherapeuticNAICS 541715, PSC AN12 | $1,499,773 |
| FA864924P0833Purchase Order, May 13, 2024, Full and Open Competition After Exclusion of Sources, 494 offers | FA8649 USAF SBIR STTR Cntrctng AFRLDepartment of the Air Force | Polyethylene Glycol-20k/8k (Peg-20k/8k): a Patented Intravenous Solution in Uncontrolled HemorrhageNAICS 541715, PSC AC32 | $109,917 |
| HT942523C0065Definitive Contract, April 26, 2024, Full and Open Competition After Exclusion of Sources, 5 offers | Army Med Res Acq ActivityDefense Health Agency | DHA SBIR Direct to Phase II - II Proposal H2D-0122: "ind-Enabling Studies of PM-208: a Novel Prehospital Anti-Shock Therapeutic"NAICS 541715, PSC AN12 | $0 |
- Places of performance
- Virginia
- Product and service codes
- AC32 National Defense R&D Services; Defense-Related Activities; Applied ResearchAN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 14 across 5 awards